Discover the potential of hydrocortisone for treating severe communityacquired pneumonia (CAP) in this insightful video. Join us as we delve into the benefits of glucocorticoids, explore the history of their use in various medical conditions, and examine the results of a recent doubleblind, randomized controlled trial published in the New England Journal of Medicine. We discuss the dosing protocol, primary and secondary outcomes, as well as the absence of major adverse effects. Find out why hydrocortisone may hold promise in improving mortality rates and preventing intubation and shock in CAP patients. Watch now to learn about this potentially gamechanging treatment option.

Show Notes: https://eddyjoemd.com/hydrocortisone...
Descript was used to edit this video: https://www.descript.com?lmref=BGOxjQ

Citation: Dequin PF, Meziani F, Quenot JP, Kamel T, Ricard JD, Badie J, Reignier J, Heming N, Plantefève G, Souweine B, Voiriot G, Colin G, Frat JP, Mira JP, Barbarot N, François B, Louis G, Gibot S, Guitton C, Giacardi C, Hraiech S, Vimeux S, L'Her E, Faure H, Herbrecht JE, Bouisse C, Joret A, Terzi N, Gacouin A, Quentin C, Jourdain M, Leclerc M, Coffre C, Bourgoin H, Lengellé C, CailleFénérol C, Giraudeau B, Le Gouge A; CRICSTriGGERSep Network. Hydrocortisone in Severe CommunityAcquired Pneumonia. N Engl J Med. 2023 Mar 21. doi: 10.1056/NEJMoa2215145. Epub ahead of print. PMID: 36942789.